title: The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.
abstract: A group of 668 stage II melanoma patients was entered into a randomized prospective study aimed at evaluating the efficacy of adjuvant BCG, 5-(dimethyltriazeno)imidazole-4-carboxamide (DTIC), or a combination of the two, given immediately after radical lymph node dissection. Of these, 176 patients received BCG and 164 BCG plus DTIC. These 340 patients had histologically proven metastatic nodes and 156 had a negative skin reactivity to BCG at the beginning of treatment. The distribution of known prognostic factors (sex, age, number of positive nodes, extracapsular invasion) was balanced in the groups of patients either with initially negative or with positive skin reactivity. All patients who were initially non-reactive to BCG developed skin reactivity after 6.7 +/- 9 BCG vaccinations. Disease-free and overall survival of patients receiving BCG or BCG + DTIC with an initially negative skin reactivity to BCG was significantly (P = 7 x 10(-3) better than that observed in patients with an initial positive skin reactivity. This finding was still evident after adjustment for other known prognostic criteria (P = 0.02). It seems likely that the initial BCG skin reactivity as such marks the prognosis; however, some therapeutic effect of BCG treatment in patients having initially no skin reactivity to BCG, can not be ruled out.
authors.affiliation: Division of Surgical Oncology B, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Cascinelli
authors.forename: P
authors.initials: P
authors.lastname: Rümke
authors.forename: R
authors.initials: R
authors.lastname: MacKie
authors.forename: A
authors.initials: A
authors.lastname: Morabito
authors.forename: R
authors.initials: R
authors.lastname: Bufalino
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000601:surgery* / Q000628:therapy; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D011897:Random Allocation; D012307:Risk Factors; D012882:Skin Tests
chemical_list: D001500:BCG Vaccine; C027168:5-(3,3-dimethyl-1-triazeno)-1-methylimidazole-4-carboxamide; D003606:Dacarbazine